Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Dapagliflozin as an Add-on to Insulin Therapy in Subjects With Type 1 Diabetes Mellitus - Study Two
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Apr 2022
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms DEPICT 2
- Sponsors AstraZeneca; Bristol-Myers Squibb
- 10 Apr 2022 Data from three studies (phase 2 (NCT01498185) and two phase 3 (DEPICT-1, NCT02268214; DEPICT-2, NCT02460978) studies) were used to characterize the dapagliflozin pharmacokinetics (PK) in patients with T1DM published in the Journal of Clinical Pharmacology
- 01 Jul 2021 Results of sub-group analysis efficacy and safety of dapagliflozin as an adjunct to insulin in Japanese patients, published in the Diabetes, Obesity and Metabolism.
- 06 Nov 2019 Results of two studies (DEPICT-1 & DEPICT-2) assessing impact of dapagliflozin on patient-reported treatment satisfaction, presented at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.